When mammary tumours were analyzed by pathological stage (Figure 2A), DMBA Only-treated PPARγ-MG KO mice exhibited a reduction in malignant mammary tumours versus PPARγ-WTs (5 ± 4% vs. 20 ± 8%, respectively; not significant). This evidence concerns the gene PPARG and cancer.